Viking Therapeutics, Inc. (NASDAQ: VKTX) is under pressure as Jim Cramer has recommended selling the stock, despite its impressive 49% increase over the past year. Investors are bracing for pivotal results from the company's obesity drug VK2735 while grappling with a disappointing $1.38 EPS loss that fell short of expectations. As analysts reassess the potential of its drug pipeline, the stock has shown volatility, reflecting a backdrop of uncertainty leading into its upcoming financial results.
“'Mad Money' host Jim Cramer weighs in on stock including: ... Viking Therapeutics.”
“Its shares are up by 49% over the past year and are down by 2.4% year-to-date.”
“Since the dip in August, Viking Therapeutics Inc. (NASDAQ:VKTX)’s shares are up by 41%.”
“Number of Hedge Fund Holdings in Q3 2024: 41”
“Its shares are up by 49% over the past year.”
“Date/Month of Cramer’s Remarks: January 15th, 2025.”
“Viking Therapeutics Inc. (NASDAQ:VKTX)”
“CNBC’s Jim Cramer explains why he is keeping an eye on shares of Viking Therapeutics.”
“'Mad Money' host Jim Cramer weighs in on stocks including: Viking Therapeutics, Altria, Zoom, and ProFrac Holdings.”
“CNBC's Jim Cramer explains why he is keeping an eye on shares of Viking Therapeutics ... VKTX.”
“Viking Therapeutics, Inc VKTX Real Time Price USD 32.75”
“VKTX -0.29 (-0.88%)”
